 annual meeting, QIAGEN introduced QIAsymphony Connect, an updated iteration of its widely deployed automated nucleic acid purification platform.){kind=link}
At this year’s Association for Molecular Pathology (AMP) annual meeting, QIAGEN introduced QIAsymphony Connect, an updated iteration of its widely deployed automated nucleic acid purification platform. With more than 3,000 first-generation instruments installed globally by the end of 2024, the new system represents a major technological evolution designed to meet the increasing demands of liquid biopsy workflows and data-driven laboratory environments.
According to QIAGEN, QIAsymphony Connect is engineered to deliver measurable improvements in extraction performance, processing speed, and end-to-end traceability, features that continue to push automated sample preparation into the era of high-resolution oncology, minimal residual disease (MRD) detection, and digitally connected laboratory ecosystems.
As labs face increasing pressure to process more complex samples with greater precision and speed, QIAsymphony Connect is designed to help them meet those challenges. Our presence at AMP 2025 highlights our commitment to advancing high-growth areas of sample technologies where QIAGEN is playing a leading role in supporting customers worldwide with novel liquid biopsy applications as well as working with our partners to create innovative advances in precision oncology.
Nitin Sood, Senior Vice President and Head of Product Portfolio & Innovation at QIAGEN
QIAsymphony Connect incorporates several substantial enhancements aimed at optimizing nucleic acid purification for high-sensitivity applications:
- Improved extraction efficiency: A refined elution process minimizes intrinsic dead volume, enabling higher nucleic acid concentrations and better recovery from large or challenging sample inputs.
- Increased throughput: The platform supports up to 50% more samples in select liquid biopsy protocols, improving laboratory productivity without sacrificing analytical quality.
- Oncology-focused performance: Built to accommodate workflows requiring large input volumes and small elution volumes, the system targets MRD monitoring and other early-detection approaches where assay sensitivity is paramount.
- Comprehensive sample traceability: Automated 2D barcode scanning for both input and eluate tubes provides fully auditable sample tracking.
- Digital connectivity: Integration with laboratory information management systems (LIMS) and QIAGEN’s remote-monitoring platform, QIAsphere, reflects an industry shift toward cloud-assisted workflow management.
- Operational scalability: Infrastructure improvements allow the instrument to scale with evolving laboratory needs and integrate more seamlessly into high-complexity environments.
Select customers currently have access to the instrument through an early-access program, with full commercial availability planned for mid-2026. QIAGEN reports that the current QIAsymphony platform will remain available during the transition period.
Complementing the launch of QIAsymphony Connect, QIAGEN is showcasing updates across its Sample to Insight portfolio, including precision oncology collaborations with Element Biosciences and Myriad Genetics.
- A joint workshop with Element Biosciences on November 12 will feature early-access data from a study led and presented by Dr. Pinar Uysal-Onganer, an associate professor at the University of Westminster, demonstrating an efficient, scalable, comprehensive genomic profiling workflow for characterizing breast cancer FFPE samples using the QIAseq xHYB Trinity CGP on the Element Biosciences Trinity technology, together with CLC Genomics Workbench and QCI Interpret. Commercial launch is anticipated in early 2026.
- Data from the collaboration with Myriad Genetics Inc. will also be presented at AMP. The two companies are working together to advance testing for homologous recombination deficiency (HRD), a genetic condition that may make certain cancers more responsive to therapy. Early results from the QIAseq xHYB HRD Panel (intended for research applications), used in a Sample to Insight workflow, demonstrate high concordance with Myriad Genetics’ MyChoice® CDx assay. Full commercialization (excluding Japan) is expected in early 2026.
QIAGEN notes that the HRD panel can be paired with its CGP counterpart to produce a unified hybrid-capture workflow capable of assessing SNVs, indels, CNVs across 724 cancer-associated genes, along with biomarker analyses for BRCA1/2, HRD, MSI, and TMB.